immunotherapy – Page 3

Timing Matters: Sequential Pembrolizumab Plus Chemoradiation Outperforms Concurrent Approach in Locally Advanced Head and Neck Cancer

By MedXY 08/07/2025

A Phase II trial finds sequential pembrolizumab after chemoradiation achieves superior locoregional control compared to concurrent administration in locally advanced head and neck squamous cell carcinoma.

Clinical Updates news Oncology Specialties

A Century of Change: How Human Innovation Transformed Lung Cancer Treatment

By MedXY 08/03/2025

Lung cancer therapy has evolved from rudimentary surgery and misdiagnosis to a precision medicine era, markedly improving outcomes through targeted therapies and immunotherapy.

Clinical Updates news

EBIN Study: Sequencing Targeted Therapy and Immunotherapy in BRAFV600-Mutant Advanced Melanoma

By MedXY 08/03/2025

A phase 2 trial found that induction targeted therapy with encorafenib and binimetinib before immune checkpoint inhibitors did not improve progression-free survival versus immune checkpoint inhibitors alone in advanced melanoma with BRAFV600E/K mutations.

Clinical Updates news Oncology Specialties

Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?

By MedXY 08/03/2025

Retifanlimab combined with carboplatin-paclitaxel significantly prolongs progression-free survival in advanced squamous cell anal cancer, offering a promising new first-line standard of care.

Clinical Updates news Oncology Specialties

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial

By MedXY 08/03/2025

The IMforte phase 3 trial demonstrates that lurbinectedin plus atezolizumab as first-line maintenance significantly prolongs progression-free and overall survival in extensive-stage small-cell lung cancer, albeit with increased hematologic toxicity.

$Subcutaneous Blinatumomab in Relapsed/Refractory B-ALL: Clinical Promise and the Future of Delivery Modalities$

Clinical Updates Hematology-Oncology news Specialties

Subcutaneous Blinatumomab in Relapsed/Refractory B-ALL: Clinical Promise and the Future of Delivery Modalities

By MedXY 08/02/2025

Subcutaneous blinatumomab demonstrates promising efficacy and manageable safety in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with potential to shift future administration paradigms.

Clinical Updates news Oncology Specialties

Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial

By MedXY 07/31/2025

Adding perioperative durvalumab to standard FLOT chemotherapy significantly improves event-free survival and pathological response in resectable gastric and gastroesophageal junction adenocarcinoma without increasing severe adverse events.

Clinical Updates news Oncology Specialties

Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial

By MedXY 07/31/2025

Tarlatamab significantly improves overall survival and reduces severe adverse events compared to chemotherapy in patients with small-cell lung cancer progressing after platinum-based therapy.

Allergy & Immunology Clinical Updates news Specialties

Cockroach Immunotherapy Modulates Key T-Cell Responses Regardless of Allergen Extract Abundance

By MedXY 07/30/2025

A randomized trial finds that subcutaneous cockroach immunotherapy effectively downregulates dominant T-cell responses in pediatric asthma, independent of allergen abundance in the therapeutic extract.

Medical News Oncology

AI-Designed Proteins Revolutionize Personalized Cancer Treatment

By MedXY 07/25/2025

AI-powered protein design offers a fast, personalized approach to cancer treatment, enhancing immune response and minimizing side effects.